Press Release

Harbour BioMed’s Batoclimab (HBM9161) Receives China CDE Breakthrough Therapy Designation for Treatment of Adult Patients with Myasthenia Gravis

January 28, 2021

Harbour BioMed
on WeChat

Back to list

Harbour BioMed’s Batoclimab (HBM9161) Receives China CDE Breakthrough Therapy Designation for Treatment of Adult Patients with Myasthenia Gravis

January 28, 2021

Cambridge, MA, Rotterdam, NL, Suzhou, CN— January 28, 2021.


Harbour BioMed (HBM) (HKEX: 02142.HK) announced today that China Center for Drug Evaluation (CDE) has granted Breakthrough Therapy designation to Batoclimab (HBM 9161), a fully human anti-FcRn monoclonal antibody (mAb), for the treatment of adult patients with Myasthenia Gravis (MG).


Myasthenia Gravis is a severely debilitating condition that manifests itself in the form of skeletal muscle contraction and weakness limiting movement and could even result in fatal respiratory failure. In China, an estimated 250,000 patients suffer from this condition. Current therapies are limited due to inadequate efficacy, safety issues or limited availability.


Batoclimab (HBM9161), a fully human anti-FcRn mAb, blocks FcRn-IgG interactions, accelerating the degradation of autoantibodies and leads to the treatment of pathogenic IgG-mediated autoimmune diseases. Earlier studies demonstrated that Batoclimab is well tolerated​ and can rapidly reduce total IgG. These findings make Batoclimab the first anti-FcRn to demonstrate a sustained IgG reduction in both ​Chinese and Caucasian populations when administered via subcutaneous (SC) injection.


According to CDE guidelines, Breakthrough Therapy designations are reserved for drugs that treat serious and/or life-threatening diseases or conditions, while demonstrating a substantial improvement over existing therapies on one or more clinically significant endpoints based on preliminary clinical evidence. The designation also indicates that the development and review of Batoclimab (HBM 9161) in adults with MG will be expedited in order to address patients’ unmet needs quicker.


“This is the first Breakthrough Therapy designation granted to HBM, highlighting the unmet needs and the potential opportunity for our expanding immunology portfolio.” said Dr. Jingsong Wang, Founder, Chairman, and CEO of HBM. “In China, large numbers of patients suffer IgG-mediated autoimmune diseases including MG, ITP, NMOSD, among others. This Breakthrough Therapy designation will enable the accelerated development of Batoclimab for MG thereby bringing this life-changing innovative drugs to patients in China sooner.” he added.



About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.

The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.  


For further information, please refer to

Media Contact:

Harbour BioMed Public Relations